Drug Profile
Research programme: phospholipase A2 inhibitors - Anthera
Alternative Names: A-003; A-101Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company; Shionogi
- Developer Anthera Pharmaceuticals
- Class
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Autoimmune disorders; Cardiovascular disorders
Most Recent Events
- 14 Mar 2012 Discontinued - Preclinical for Autoimmune disorders in USA (unspecified route)
- 14 Mar 2012 Discontinued - Preclinical for Cardiovascular disorders in USA (unspecified route)
- 09 Apr 2011 Preclinical trials in Autoimmune disorders in USA (unspecified route)